Search
for

    Learn

    5 / 801 results

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

      learn Valproic acid

      an anticonvulsant repurposed for hair loss via histone inhibition

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Research

    5 / 671 results

    Community Join

    5 / 1000+ results

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community Has anyone else seen this encouraging verteporfin case study?

      in Progress Pictures  35 upvotes 2 years ago
      The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

      community Does anyone know of the actual effectiveness of the DP2 inhibitors?

      in Question  4 upvotes 8 years ago
      Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

      community Anagenic is trying to compound Gt20029

      in Treatment  56 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.